Palo Alto Investors LP Alkermes Plc. Transaction History

Palo Alto Investors LP

$501 Million
Q1 2025

A detailed history of Palo Alto Investors LP transactions in Alkermes Plc. stock. As of the latest transaction made, Palo Alto Investors LP holds 221,513 shares of ALKS stock, worth $6.39 Million. This represents 1.46% of its overall portfolio holdings.

Number of Shares

221,513

Previous 289,308 23.43%

Holding current value

$6.39 Million

Previous $8.32 Million 12.09%

% of portfolio

1.46%

Previous 1.33%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$28.08 - $36.0 $1.9 Million - $2.44 Million	-67,795 Reduced 23.43%	221,513 $7.31 Million
Q4 2024 Feb 14, 2025	SELL	$25.7 - $31.46 $2.45 Million - $3 Million	-95,348 Reduced 24.79%	289,308 $8.32 Million
Q3 2024 Nov 14, 2024	SELL	$23.01 - $28.55 $2.55 Million - $3.17 Million	-110,936 Reduced 22.38%	384,656 $10.8 Million
Q1 2024 May 15, 2024	SELL	$26.4 - $32.56 $2.85 Million - $3.51 Million	-107,808 Reduced 17.87%	495,592 $13.4 Million
Q2 2022 Aug 15, 2022	SELL	$26.4 - $30.54 $1.85 Million - $2.14 Million	-70,171 Reduced 10.42%	603,400 $18 Million
Q1 2022 May 16, 2022	SELL	$23.07 - $27.99 $1.86 Million - $2.26 Million	-80,629 Reduced 10.69%	673,571 $17.7 Million
Q4 2021 Feb 14, 2022	BUY	$21.47 - $32.08 $3.53 Million - $5.27 Million	164,300 Added 27.85%	754,200 $17.5 Million
Q3 2021 Nov 15, 2021	BUY	$23.37 - $32.13 $2.4 Million - $3.3 Million	102,800 Added 21.1%	589,900 $18.2 Million
Q1 2021 May 17, 2021	BUY	$18.21 - $23.2 $6.13 Million - $7.81 Million	336,502 Added 223.44%	487,100 $9.1 Million
Q4 2020 Feb 16, 2021	BUY	$15.39 - $22.1 $2.32 Million - $3.33 Million	150,598 New	150,598 $3 Million

Others Institutions Holding ALKS

# of Institutions

410

Shares Held

177M

Call Options Held

229K

Put Options Held

436K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.74B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.

Account

Palo Alto Investors LP Alkermes Plc. Transaction History